pharmaphorum

JANUARY 18, 2022

It’s an amazing opportunity to put their knowledge and experience in dermatology, together with our expertise in molecular glues to accelerate drug discovery to treat skin diseases. It also builds on complementary core expertise of each partner to facilitate research and drug development.”.

Dermatology 52

Dermatology Protein Pharma Companies Research 52

The Pharma Data

JANUARY 12, 2021

Dr Graham is a medicines development expert and Infectious Diseases Epidemiologist with global Biotech and Pharma R&D experience in Phase I-IV therapeutics as well as in-vivo & in-vitro diagnostics, across many modalities. He has in depth Global Development Expertise (e.g. NEW YORK and LONDON, Jan. Graham earned an M.D.,

Life Science 52

Life Science Antibody In-Vivo In-Vitro 52

The Pharma Data

NOVEMBER 8, 2020

Almirall strengthens its leadership in medical dermatology by reinforcing its management team in France and obtaining reimbursement in France of Ilumetri ® (tildrakizumab) for treating moderate to severe chronic plaque psoriasis in adults. We have done this by both internal talent development as well as by external hires.

Dermatology 52

Dermatology Sales Marketing Production 52

pharmaphorum

SEPTEMBER 30, 2022

The Spanish drugmaker is paying $15 million upfront for rights to IL-2 mutant fusion protein (IL-2 mu-Fc) SIM0278 outside the Greater China region, with another $492 million pledged in development and commercial milestone payments if the drug works across multiple autoimmune indications. Last year, Merck & Co paid $1.85

Licensing 52

Licensing Licensing Dermatology Drugs 52

Roots Analysis

MARCH 3, 2022

Since the approval of Soliris® in 2007, an anti-C5 antibody, the field of complement drug discovery has gained significant attention. Currently, nine complement therapeutics are commercially available, while around 190 molecules are under development for various disease indications. Next Generation Complement Therapeutics.

Drug Delivery Systems 52

Drug Delivery Systems Marketing Immune Response Dermatology 52

The Pharma Data

AUGUST 16, 2021

Lebrikizumab is a novel monoclonal antibody (mAb) that binds soluble IL-13 with high affinity, has high bioavailability, a long half-life and blocks IL-13 signaling. associate professor of dermatology at George Washington University School of Medicine and Health Sciences in Washington, DC, and a principal investigator of the ADvocate 2 trial.

Trials 40

Trials Dermatology Bioavailability Medicine 40

pharmaphorum

NOVEMBER 28, 2022

Tralokinumab is a high-affinity human monoclonal antibody that specifically targets and neutralises interleukin (IL)-13 cytokine, which plays an important role in the immune and inflammatory processes underlying AD signs and symptoms.

Dermatology 52

Dermatology Trials Medicine Antibody 52

The Pharma Data

DECEMBER 17, 2020

Kurtz brings more than 26 years of experience in global manufacturing, engineering, supply chain, CMC development and program management for drugs and devices at various stages of development. Cadavid will be responsible for the strategy, direction and execution of the company’s clinical development programs.

Development 52

Development Gene Therapy Engineer Life Science 52

pharmaphorum

AUGUST 16, 2021

billion to take control of lebrikizumab’s developer Dermira last year after the antibody showed promising results in phase 2b trials, and has been waiting for the results of the phase 3 trials to see if that was a good move. Lilly shelled out $1.1

Antibody 52

Antibody Trials Drugs Marketing 52

pharmaphorum

JANUARY 6, 2023

a Los Angeles area-based, late-stage clinical biopharma, with additional operations in the San Francisco Bay area, has announced it is acquiring privately held ValenzaBio – which develops therapies for autoimmune and inflammatory diseases – in an all-stock transaction. ACELYRIN, Inc.,

Trials 59

Trials Marketing Protein Antibody 59

pharmaphorum

JUNE 2, 2021

The deal gives Amgen rights to the KHK4083 antibody in all countries except Kyowa’s home market of Japan, and is back-loaded with potential milestone payments worth another $850 million plus royalties on sales. Kyowa will co-promote the drug in the US if approved, with opt-in rights in some other countries as well.

Drugs 52

Drugs Licensing Licensing Sales 52

pharmaphorum

APRIL 26, 2021

UK biotech Avillion has reported positive mid-stage results with chronic psoriasis drug sonelokimab, which it is developing with Merck KGaA as an alternative to drugs like Novartis’ Cosentyx. . The drug is a nanobody, a molecule around one-tenth the size of a regular antibody derived from camelid species such as the llama.

Antibody 52

Antibody Drugs Marketing Licensing 52

The Pharma Data

JULY 11, 2021

Department of Dermatology, Venereology and Allergology, Charité – Universitätsmedizin in Berlin, Germany. The efficacy of TAKHZYRO to prevent HAE attacks over the long term will be an important consideration for patients and physicians as they develop a treatment plan for patients that is focused on reducing the number of HAE attacks.”. “For

Allergies 52

Allergies Antibody Recombinant DNA Technology Production 52

The Pharma Data

JUNE 7, 2022

vice president of global immunology development and medical affairs at Lilly. 1-2 Lebrikizumab is a novel, monoclonal antibody (mAb) that binds to the interleukin-13 (IL-13) protein with high affinity to specifically prevent the formation of IL-13R? .” Type 2 receptor) which blocks downstream signaling through the IL-13 pathway.3-7

Trials 40

Trials Clinical Trials Clinical Trials Medicine 40

pharmaphorum

APRIL 28, 2021

Lilly chief scientific officer Daniel Skovronsky said that the company will focus on developing mirikizumab for ulcerative colitis in Crohn’s disease indications “where unmet medical need is higher and where we believe the potential of the IL-23p19 mechanism to create a new standard of care is greater.”

Marketing 52

Marketing Trials Drugs Antibody 52

pharmaphorum

MAY 25, 2022

Vtama (tapinarof) – originally developed by GlaxoSmithKline – is a first-in-class, once-daily topical therapeutic aryl hydrocarbon receptor modulating agent (TAMA) and has been approved by the US regulator with a broad label spanning mild, moderate, and severe psoriasis and an unlimited duration of use.

Drugs 52

Drugs FDA Approval Licensing Licensing 52

XTalks

AUGUST 7, 2024

Related: New Sotyktu Commercial for Plaque Psoriasis: Living Life Without a “Filter” Treatments for Psoriasis Over the years, advancements in medical research have led to the development of more effective treatments for psoriasis. These treatments include topical therapies, phototherapy, systemic medications and biologics.

FDA Approval 52

FDA Approval Genetics Antibody Drugs 52

Pharmaceutical Technology

MAY 8, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Anti-influenza antibody compositions. However, not all innovations are equal and nor do they follow a constant upward trend.

Antibody 246

Antibody Vaccination Vaccine Dermatology 246

Pharmaceutical Technology

MAY 30, 2023

Lecanemab by Eisai Co Ltd, a monoclonal antibody therapy marketed for Alzheimer’s disease, is predicted to achieve the most significant commercial debut. which is the licensee of lebrikizumab, recently reported favourable outcomes for lebrikizumab through a novel secondary analysis of the Phase III clinical development programme.

Drugs 264

Drugs Sales Antibody Dermatology 264

The Pharma Data

MARCH 18, 2022

Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and novel LAG-3-blocking antibody relatlimab 1. 2 The combination of nivolumab (anti-PD-1) and relatlimab (anti-LAG-3) results in increased T-cell activation compared to the activity of either antibody alone.1

Antibody 52

Antibody HR Trials Dermatology 52

pharmaphorum

SEPTEMBER 2, 2022

German drugmaker Boehringer Ingelheim has its first regulatory approval for spesolimab, its antibody therapy for rare and life-threatening skin disorder generalised pustular psoriasis (GPP), in the US. Mortality rates following GPP flares range from 2% to 16%, with most deaths caused by septic shock and cardiorespiratory failure.

Drugs 105

Drugs Antibody FDA Approval Trials 105

Pharmaceutical Technology

MAY 8, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Antibody 147

Antibody Vaccination Vaccine Dermatology 147

The Pharma Data

DECEMBER 30, 2020

billion acquisition of immuno-oncology company Forty Seven and its lead asset, magrolimab, a monoclonal antibody in the clinic for several cancers, including myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and diffuse large B-cell lymphoma (DLBCL). It began in May with the $4.9 Magrolimab targets CD47. But the U.K.-based

Antibody 52

Antibody Allergies Branding Dermatology 52

The Pharma Data

AUGUST 19, 2020

Momenta), a company that discovers and develops novel therapies for immune-mediated diseases, in an all cash transaction for approximately $6.5 The transaction will include full global rights to nipocalimab (M281), a clinically validated, potentially best-in-class anti-FcRn antibody. NEW BRUNSWICK, N.J., Food and Drug Administration.

Production 52

Production Dermatology Development Containment 52

The Pharma Data

OCTOBER 9, 2021

Tezepelumab is being developed by AstraZeneca in collaboration with Amgen and is under Priority Review for patients with asthma in the US. 4,5,6,7 Tezepelumab is in development for potential indications including asthma, chronic obstructive pulmonary disease, nasal polyps and chronic spontaneous urticaria.

Drugs 52

Drugs Sales Medicine Dermatology 52

The Pharma Data

AUGUST 1, 2021

Saphnelo is a first-in-class type I interferon receptor antibody and the only new medicine in over a decade for patients with systemic lupus erythematosus . 13 More than 50% of patients with SLE develop permanent organ damage, caused by the disease or existing treatments, which exacerbates symptoms and increases the risk of mortality.

Trials 52

Trials Clinical Development Antibody Medicine 52

The Pharma Data

AUGUST 19, 2020

Momenta), a company that discovers and develops novel therapies for immune-mediated diseases, in an all cash transaction for approximately $6.5 The transaction will include full global rights to nipocalimab (M281), a clinically validated, potentially best-in-class anti-FcRn antibody. NEW BRUNSWICK, N.J. , Food and Drug Administration.

Production 40

Production Dermatology Development Containment 40

The Pharma Data

AUGUST 3, 2021

billion in acquired in-process research & development (acquired IPR&D) associated with our acquisition of Five Prime Therapeutics, partially offset by increased revenues. We expect that recovery in the dermatology segment will continue to progress over the coming quarters. GAAP earnings per share (EPS) decreased 73% to $0.81

Sales 52

Sales Production Antibody Development 52

The Pharma Data

APRIL 28, 2021

These and other data from real-world settings and clinical trials, including the Dupixent open-label extension (OLE) trials, will be presented at the American Academy of Dermatology (AAD VMX 2021), April 23-25, and at the 20 th European Society for Pediatric Dermatology Annual Meeting (ESPD 2021), May 12-14.

Dermatology 40

Dermatology Trials Clinical Trials Clinical Trials 40

The Pharma Data

AUGUST 17, 2021

About JEMPERLI (dostarlimab-gxly) JEMPERLI is a programmed death receptor-1 (PD-1)-blocking antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2. The collaboration has resulted in three monospecific antibody therapies that have progressed into the clinic. Immune-Mediated Pneumonitis.

FDA Approval 52

FDA Approval Antibody DNA Hormones 52

Delveinsight

AUGUST 13, 2020

GSK is developing this therapy in collaboration with Innoviva, Inc., SAR440340 History: Regeneron and Sanofi are currently studying REGN3500 in respiratory and dermatological diseases where inflammation is thought to play an underlying role. Preclinical research showed SAR440340 blocked several markers of both types of inflammation.

Antibody 40

Antibody Medicine Trials Development 40

The Pharma Data

MARCH 28, 2022

The focus of the event is on Dupixent ® (dupilumab), a key growth driver, and Sanofi’s rapidly advancing pipeline, highlighting dermatological, respiratory and gastrointestinal diseases as priority therapeutic areas. Two complementary candidates for COPD , developed in collaboration with Regeneron, targeting distinct subpopulations.

Medicine 52

Medicine Sales Clinical Development Development 52

The Pharma Data

MAY 15, 2023

Safety results through 24 weeks were generally consistent with the known safety profile of Dupixent in its approved dermatology indication. About Dupixent Dupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant.

Medicine 40

Medicine Trials Dermatology FDA Approval 40

The Pharma Data

MARCH 23, 2022

The only large-scale prospective study in dermatology designed to generate key disease insights among Black, Hispanic, Asian, Indigenous and other people of color Study reinforces Janssen’s commitments to inclusive clinical research and addressing health inequities. 11 TREMFYA is approved in the U.S.,

Dermatology 52

Dermatology Clinical Research Research Medicine 52

The Pharma Data

MARCH 15, 2022

Fasenra Fasenra (benralizumab) is a monoclonal antibody that binds directly to IL-5 receptor alpha on eosinophils and attracts natural killer cells to induce rapid and near-complete depletion of blood and tissue eosinophils in most patients via apoptosis (programmed cell death). 2 The trial is expected to read out in the second half of 2023.

Trials 52

Trials Medicine Licensing Licensing 52

pharmaphorum

SEPTEMBER 29, 2022

The disorder – driven by type 2 inflammation characterised by an antibody-based immune response – causes hard lumps or nodules to form on the skin that are so itchy they can lead patients to scratch themselves to the point of bleeding or pain. Development in peanut allergy has also been discontinued, said Sanofi in its second-quarter update.

Drugs 69

Drugs Immune Response Allergies Sales 69

The Pharma Data

JULY 8, 2021

Tezepelumab is being developed by AstraZeneca in collaboration with Amgen. AstraZeneca continues to lead development and Amgen continues to lead manufacturing. 1 The Prescription Drug User Fee Act date, the FDA action date for their regulatory decision, is during the first quarter of 2022.

Trials 52

Trials Medicine Sales Clinical Trials 52